-

10:58:32 PM

NRXP Stock News

NRXP - NRX Pharmaceuticals Inc

03/18/22 5:00 AM

Nasdaq : NRXP

management

NRx Pharmaceuticals, Inc. Appoints Ira Strassberg as Chief Financial Officer and Treasurer

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage pharmaceutical company, announced today that the company's Board of Directors appointed Ira Strassberg as Chief Financial Officer and Treasurer effective March 15, 2022."Ira has been serving NRx

RHEA-AI

neutral

03/08/22 10:25 PM

Nasdaq : NRXP

management

NRx Pharmaceuticals Announces Leadership Transition

NRx Pharmaceuticals (Nasdaq: NRXP) ("NRx" or the "Company"), a clinical-stage, biopharmaceutical company, today announced that Jonathan Javitt, MD, MPH, has retired as Chief Executive Officer effective immediately. The Board of Directors appointed Robert

RHEA-AI

positive

02/15/22 8:32 AM

Nasdaq : NRXP

covid-19

NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment

NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today announced results of a review conducted by the Therapeutics and Prevention Data Safety and Monitoring Board (DSMB) of the National Institute of Allergy and Infectious

RHEA-AI

neutral

02/11/22 8:01 AM

Nasdaq : NRXP

covid-19

NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational Vaccine

RHEA-AI

neutral

02/02/22 7:06 PM

Nasdaq : NRXP

NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq Rules

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP (or the "Company"), a Delaware corporation, today announced that it has closed its previously announced private placement priced at a premium to market under Nasdaq rules of 7,824,727 shares of its common stock and

RHEA-AI

neutral

01/31/22 7:59 AM

Nasdaq : NRXP

NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq Rules

NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 7,824,727 shares of common stock in a private placement priced at a premium to

RHEA-AI

neutral

01/27/22 6:51 AM

Nasdaq : NRXP

NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine may produce effective levels of neutralizing antibody

RHEA-AI

neutral

01/26/22 6:51 AM

Nasdaq : NRXP

NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, has received a first safety report from a Southwestern hospital where physicians have administered ZYESAMI® (Aviptadil) to patients with COVID-19 respiratory failure. These

RHEA-AI

neutral

01/18/22 6:48 AM

Nasdaq : NRXP

covid-19

NRx Pharmaceuticals Announces Expansion of ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID-19 Respiratory Failure who have Exhausted All Approved Treatments

ZYESAMI ® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH) NRx will continue to provide ZYESAMI to hospitals enrolled in NRx’s Expanded Access Protocol under US Food and Drug Administration guidelines NRx is also making ZYESAMI

RHEA-AI

neutral

01/14/22 2:34 PM

Nasdaq : NRXP

NRx Responds to Relief’s Allegations of January 14, 2022

Neither NRx nor Jonathan Javitt accused current Relief management or board of a criminal past. The lawsuit identifies FINRA actions against Dr. Sevelraju, prior securities investigation, and civil fines against Dr. John Paul Waymack, and a prior securities fraud conviction, incarceration, and SEC

RHEA-AI

very negative

Prev 1 2 3 4 5 6 7 8 9 10 Next

NRXP Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.nrxpharma.com
Security nameNRX Pharmaceuticals Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees4
Address2645 N Federal Hwy Ste 230
StateFlorida
CityDelray Beach
Zip33483-6111
CountryUS
Phone13107342300

About NRX Pharmaceuticals Inc

NeuroRx draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. NeuroRx recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp ('BRPA'), and intends to apply for listing on the NASDAQ under the proposed symbol 'NRXP'.